% alzhub.org library filter
% Source: https://alzhub.org/research?author=Sperling+R&access=free
% 12 entries, in the order the page lists them. Built from alzhub.org's own records.
% 0 entries have no readable author in the source record and carry no author field.

@article{salloway2014-24450891,
  author  = {Salloway, S. and Sperling, R. and Fox, N. C. and Blennow, K. and Klunk, W. and Raskind, M. and Sabbagh, M. and Honig, L. S. and others},
  title   = {{Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease}},
  journal = {The New England journal of medicine},
  year    = {2014},
  doi     = {10.1056/nejmoa1304839},
  pmid    = {24450891},
  url     = {https://doi.org/10.1056/nejmoa1304839}
}

@article{salloway2009-19923550,
  author  = {Salloway, S. and Sperling, R. and Gilman, S. and Fox, N. C. and Blennow, K. and Raskind, M. and Sabbagh, M. and Honig, L. S. and others},
  title   = {{A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease}},
  journal = {Neurology},
  year    = {2009},
  doi     = {10.1212/wnl.0b013e3181c67808},
  pmid    = {19923550},
  url     = {https://doi.org/10.1212/wnl.0b013e3181c67808}
}

@article{sperling2021-33464300,
  author  = {Sperling, R. and Henley, D. and Aisen, P. S. and Raman, R. and Donohue, M. C. and Ernstrom, K. and Rafii, M. S. and Streffer, J. and others},
  title   = {{Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2021},
  doi     = {10.1001/jamaneurol.2020.4857},
  pmid    = {33464300},
  url     = {https://doi.org/10.1001/jamaneurol.2020.4857}
}

@article{salloway2011-21917766,
  author  = {Salloway, S. and Sperling, R. and Keren, R. and Porsteinsson, A. P. and van Dyck, C. H. and Tariot, P. N. and Gilman, S. and Arnold, D. and others},
  title   = {{A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease}},
  journal = {Neurology},
  year    = {2011},
  doi     = {10.1212/wnl.0b013e3182309fa5},
  pmid    = {21917766},
  url     = {https://doi.org/10.1212/wnl.0b013e3182309fa5}
}

@article{liu2018-29429971,
  author  = {Liu, E. and Wang, D. and Sperling, R. and Salloway, S. and Fox, N. C. and Blennow, K. and Scheltens, P. and Schmidt, M. E. and others},
  title   = {{Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab}},
  journal = {Neurology},
  year    = {2018},
  doi     = {10.1212/wnl.0000000000005060},
  pmid    = {29429971},
  url     = {https://doi.org/10.1212/wnl.0000000000005060}
}

@article{liu2015-26208959,
  author  = {Liu, E. and Schmidt, M. E. and Margolin, R. and Sperling, R. and Koeppe, R. and Mason, N. S. and Klunk, W. E. and Mathis, C. A. and others},
  title   = {{Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials}},
  journal = {Neurology},
  year    = {2015},
  doi     = {10.1212/wnl.0000000000001877},
  pmid    = {26208959},
  url     = {https://doi.org/10.1212/wnl.0000000000001877}
}

@article{vandyck2025-41355080,
  author  = {van Dyck, C. H. and Sperling, R. and Johnson, K. and Dhadda, S. and Kanekiyo, M. and Li, D. and Gee, M. and Hersch, S. and Irizarry, M. and Kramer, L.},
  title   = {{Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the Clarity AD open-label extension study}},
  journal = {Alzheimer's \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.70905},
  pmid    = {41355080},
  url     = {https://doi.org/10.1002/alz.70905}
}

@article{grill2024-37830926,
  author  = {Grill, J. D. and Flournoy, C. and Dhadda, S. and Ernstrom, K. and Sperling, R. and Molina-Henry, D. and Tranotti, K. and Harris, R. and others},
  title   = {{Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease}},
  journal = {Annals of neurology},
  year    = {2024},
  doi     = {10.1002/ana.26819},
  pmid    = {37830926},
  url     = {https://doi.org/10.1002/ana.26819}
}

@article{sperling2012-22305802,
  author  = {Sperling, R. and Salloway, S. and Brooks, D. J. and Tampieri, D. and Barakos, J. and Fox, N. C. and Raskind, M. and Sabbagh, M. and others},
  title   = {{Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis}},
  journal = {The Lancet. Neurology},
  year    = {2012},
  doi     = {10.1016/s1474-4422(12)70015-7},
  pmid    = {22305802},
  url     = {https://doi.org/10.1016/s1474-4422(12)70015-7}
}

@article{gomperts2016-27654968,
  author  = {Gomperts, S. N. and Locascio, J. J. and Makaretz, S. J. and Schultz, A. and Caso, C. and Vasdev, N. and Sperling, R. and Growdon, J. H. and others},
  title   = {{Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases}},
  journal = {JAMA neurology},
  year    = {2016},
  doi     = {10.1001/jamaneurol.2016.3338},
  pmid    = {27654968},
  url     = {https://doi.org/10.1001/jamaneurol.2016.3338}
}

@article{greenberg2020-31827267,
  author  = {Greenberg, S. M. and Bacskai, B. J. and Hernandez-Guillamon, M. and Pruzin, J. and Sperling, R. and van Veluw, S. J.},
  title   = {{Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways}},
  journal = {Nature reviews. Neurology},
  year    = {2020},
  doi     = {10.1038/s41582-019-0281-2},
  pmid    = {31827267},
  url     = {https://doi.org/10.1038/s41582-019-0281-2}
}

@article{bonomi2024-38038976,
  author  = {Bonomi, S. and Lu, R. and Schindler, S. E. and Bui, Q. and Lah, J. J. and Wolk, D. and Gleason, C. E. and Sperling, R. and others},
  title   = {{Relationships of Cognitive Measures with Cerebrospinal Fluid but Not Imaging Biomarkers of Alzheimer Disease Vary between Black and White Individuals}},
  journal = {Annals of neurology},
  year    = {2024},
  doi     = {10.1002/ana.26838},
  pmid    = {38038976},
  url     = {https://doi.org/10.1002/ana.26838}
}